Familial medullary thyroid carcinoma secondary to an SLC30A9 intragenic deletion and translation reinitiation

This study identifies a novel heterozygous intragenic *SLC30A9* deletion as the causative factor in *RET*-negative familial medullary thyroid carcinoma, demonstrating that the resulting N-terminally truncated proteins, produced via translation reinitiation, drive oncogenesis through increased stability and enhanced cell proliferation.

The Gist

The Mystery of the "Silent" Thyroid Cancer

Imagine the human body as a massive, bustling city. In this city, there is a specific neighborhood called the Thyroid, which produces tiny security guards called C-cells. Usually, these guards stay put, but sometimes they go rogue and form a tumor called Medullary Thyroid Carcinoma (MTC).

For decades, doctors knew that in families where this cancer runs in the bloodline (Familial MTC), the culprit was almost always a broken instruction manual for a protein called RET. Think of RET as the city's "Master Traffic Light." If the light is stuck on green, traffic (cell growth) never stops, and chaos ensues.

However, in a few families, doctors looked at the "Master Traffic Light" (the RET gene) and found it was perfectly fine. Yet, the cancer was still happening. It was like a crime scene where the usual suspect had a perfect alibi. The question was: Who else is breaking the law?

The New Suspect: A Missing Page in the Manual

The researchers in this study investigated two large, related families where the "Master Traffic Light" (RET) was working, but the cancer was still spreading. They acted like genetic detectives, using high-tech tools to scan the entire library of the human genome (the "Instruction Manual" of life).

They found the culprit: a gene called SLC30A9.

Think of the SLC30A9 gene as a Factory Blueprint for a machine that manages zinc (a vital mineral) inside the cell's power plants (mitochondria). In these families, a chunk of the blueprint was missing. Specifically, a 40,000-letter section of the manual (covering parts 2 through 7 of the gene) had been deleted.

The Twist: The "Ghost" Machine

Here is where it gets tricky. Usually, if you delete a huge chunk of a blueprint, the factory stops working entirely. The cell's quality control system (called Nonsense-Mediated Decay) sees the broken manual, tears it up, and throws it in the trash. No machine gets built.

But in this case, something strange happened. The cell's quality control system missed the error. The broken manual survived.

Because the first part of the manual (the "Start" button) was gone, the factory didn't know where to begin. So, it skipped ahead to the next available "Start" button it could find further down the page. It started building the machine from the middle, ignoring the beginning.

The Analogy: Imagine a recipe for a cake. You cut out the first 7 pages (the ingredients and mixing instructions). The baker sees the missing pages, but instead of stopping, they skip to page 8, find a sentence that says "Add eggs," and start baking from there. The result isn't a cake; it's a weird, half-baked, sticky mess.

The Dangerous Result: A Super-Stable Monster

This "half-baked" machine (the truncated protein) turned out to be dangerous for two reasons:

1. It wouldn't die: Normal machines are recycled after a while. This mutant machine was like a zombie; it refused to break down. It became incredibly stable and piled up in the cell.
2. It went to the wrong place: The normal machine belongs in the cell's power plant (mitochondria). But because the "address label" (the N-terminus) was cut off, this mutant machine got lost. It ended up clustering in the wrong part of the cell (the endoplasmic reticulum), forming sticky clumps.

When the researchers put this mutant machine into cancer cells, the cells started growing faster and forming more colonies. It turned a "broken" gene into a super-charged, cancer-causing engine.

Why This Matters

This discovery is a game-changer for three reasons:

• New Detective Work: It proves that Familial Medullary Thyroid Cancer isn't only about the RET gene. There are other suspects, like this SLC30A9 deletion, that we need to look for.
• A New Mechanism: It shows that cancer can be caused not just by "breaking" a gene, but by restarting it in the wrong place. It's a "Gain of Function" (getting a superpower) rather than a "Loss of Function" (losing a job).
• Saving Lives: Now, doctors can test family members for this specific deletion. If a child carries it, doctors can monitor them closely and remove the thyroid before the cancer becomes aggressive, potentially saving lives.

The Bottom Line

The researchers found a hidden genetic "glitch" in two families. Instead of destroying the cell's instructions, the glitch caused the cell to build a weird, super-stable, misplaced machine that drove the cells to grow out of control. It's a reminder that in the complex city of our bodies, sometimes the problem isn't that the lights are out, but that someone is trying to drive a car with the steering wheel cut off.

Technical Summary

1. Problem Statement

• Clinical Context: Medullary Thyroid Carcinoma (MTC) is a neuroendocrine tumor of the thyroid C-cells. While ~75% of cases are sporadic, familial forms (fMTC) account for the remainder.
• The Gap: Over 95% of familial MTC cases are caused by germline activating mutations in the RET proto-oncogene. However, a subset of families (<5%) presents with fMTC but lacks pathogenic RET mutations. The genetic etiology for these "RET-negative" fMTC cases has remained largely unidentified, hindering predictive testing and clinical management.
• Objective: To identify the causative genetic mutation in two large, related families with confirmed RET-negative fMTC and elucidate the molecular mechanism driving tumorigenesis.

2. Methodology

The study employed a multi-modal approach combining clinical phenotyping, advanced genomics, and functional biology:

• Cohort: Two large index families (Family 1 and Family 2) with 21 affected individuals across four generations, plus seven additional smaller families with RET-negative fMTC or fMTC-like phenotypes.
• Genomic Analysis:
  • Linkage Analysis: Performed on 40 individuals using SNP genotyping (Illumina CytoSNP12) to identify shared chromosomal regions.
  • Sequencing: Whole-exome sequencing (WES) and Whole-genome sequencing (WGS) were conducted on selected affected individuals to filter for rare variants within linked regions.
  • Copy Number Variant (CNV) Detection: High-density array comparative genomic hybridization (HD-aCGH) was used to screen for structural variants missed by sequencing.
  • Validation: Sanger sequencing, RT-PCR, and MLPA were used to confirm breakpoints and segregation.
• Functional Characterization:
  • Transcriptomics: RNA-sequencing of patient-derived lymphoblastoid cells and fibroblasts to assess gene expression and splicing.
  • Chromatin Conformation: Hi-C and UMI-4C experiments to determine if the deletion altered topologically associating domains (TADs) or regulatory interactions of neighboring genes.
  • In Vitro Models:
    • Knockdown: shRNA-mediated silencing of SLC30A9 in MTC (TT) cells to test loss-of-function hypotheses.
    • Overexpression: Lentiviral transduction of wild-type (WT) and mutant SLC30A9 constructs into HEK293T and TT cells.
    • Protein Analysis: Western blotting, immunofluorescence (colocalization with mitochondria/ER), and cycloheximide chase assays to assess protein stability and localization.
  • Oncogenic Assays: Cell proliferation (Alamar Blue/Incucyte) and colony-forming assays to measure oncogenic potential.

3. Key Results

A. Genetic Discovery

• Linkage: A significant linkage peak (LOD score 3.93) was identified on chromosome 4p13.
• Mutation Identification: HD-aCGH revealed a novel, heterozygous 40,348 bp intragenic deletion in the SLC30A9 gene (chr4:41,998,016-42,038,363; hg19). This deletion encompasses exons 2 through 7.
• Segregation: The deletion perfectly co-segregated with the disease phenotype in all 21 affected individuals and obligate carriers across both families. It was not found in the general population databases (gnomAD, DGV, ClinVar).
• Specificity: No SLC30A9 deletions or point mutations were found in the seven additional RET-negative families or a cohort of 108 sporadic RET-negative MTC patients, suggesting this is a "private" mutation specific to these kindreds.

B. Molecular Mechanism: Translation Reinitiation

• NMD Evasion: The deletion causes a frameshift leading to a premature stop codon (p.Glu37Alafs*11). Contrary to typical loss-of-function mutations, the mutant mRNA evades nonsense-mediated decay (NMD). This was confirmed by the lack of mRNA accumulation upon cycloheximide treatment.
• Translation Reinitiation: The mutant transcript undergoes translation reinitiation from downstream in-frame AUG codons (Met241 in exon 8 and Met266 in exon 9).
• Protein Products: This results in the production of N-terminally truncated SLC30A9 proteins (~30-40 kDa) lacking the N-terminal mitochondrial targeting sequence.
• Altered Localization & Stability:
  • WT SLC30A9 localizes to mitochondria.
  • Mutant truncated proteins lose mitochondrial localization and instead aggregate in the endoplasmic reticulum (ER) (colocalizing with calreticulin).
  • The mutant proteins exhibit increased stability (decreased turnover) compared to WT.

C. Functional Oncogenicity

• Loss-of-Function vs. Gain-of-Function: Knockdown of SLC30A9 in TT cells did not affect cell viability, ruling out a simple loss-of-function mechanism.
• Gain-of-Function: Expression of the mutant SLC30A9 in TT cells significantly increased cell proliferation and clonogenic capacity compared to controls.
• Histology: Tumor samples from affected carriers showed classic low-grade MTC features with reduced SLC30A9 protein expression (due to the truncation) compared to sporadic controls.

4. Key Contributions

1. Novel Gene Discovery: Identifies SLC30A9 (a zinc transporter) as a new susceptibility gene for familial MTC, expanding the genetic landscape beyond RET.
2. Mechanistic Insight: Demonstrates that a structural genomic variant (large deletion) can drive cancer via a gain-of-function mechanism involving translation reinitiation and NMD evasion, rather than the classic loss-of-function or dominant-negative mechanisms.
3. Clinical Implications:
   • Provides a diagnostic target for RET-negative fMTC families.
   • Suggests that carriers of this deletion require early screening (starting ~age 5) and prophylactic thyroidectomy once calcitonin levels rise, similar to moderate-risk RET mutations.
4. Paradigm Shift: Highlights that structural variants causing in-frame deletions can lead to oncogenic truncated proteins, a mechanism previously under-recognized in cancer susceptibility syndromes.

5. Significance

This study resolves the genetic etiology of a large, previously unexplained familial MTC kindred. It challenges the assumption that large deletions in tumor suppressor genes always result in haploinsufficiency or loss-of-function. Instead, it reveals a complex pathogenic pathway where a deletion creates a stable, mislocalized, and oncogenic truncated protein.

The findings underscore the importance of investigating structural variants and non-canonical translation mechanisms in "negative" genetic cases. Clinically, this enables predictive genetic testing for at-risk family members, allowing for timely surgical intervention to prevent metastatic disease. The study also suggests that SLC30A9 may play a broader role in cancer biology, as its overexpression has been linked to other malignancies, though the specific mechanism here is unique to this deletion.